SRF
SRF Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
SRF Q3 FY26 key numbers
- Revenue
- Pharma Segment: Positive traction with increased molecules and customers; second pharma intermediate plant (INR180 crore capex) commissioning in 8 months to support growth.
As stated in SRF's Q3 FY26 earnings call transcript · published 22 Aug 2026. Reported figures, not investment advice.
The short version
Chemicals Business: Revenue grew 22% YoY in Q3 FY26, driven by refrigerant volumes and realizations. - Specialty Chemicals: Facing pricing pressure due to Chinese competition; volumes protected, but growth delayed. SRF is confident about sustainable growth driven by its robust pipeline, clear strategy, and committed execution team.
From SRF's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Chemicals Business: Revenue grew 22% YoY in Q3 FY26, driven by refrigerant volumes and realizations.
- Specialty Chemicals: Facing pricing pressure due to Chinese competition; volumes protected, but growth delayed. Expect better demand in Q4 FY26 due to deferred orders.
- Agrochemicals: Signs of revival noticed; strong pipeline of new molecules gives confidence for a strong finish to the year.
- Pharma Segment: Positive traction with increased molecules and customers; second pharma intermediate plant (INR180 crore capex) commissioning in 8 months to support growth.
- Fluorochemicals (Refrigerants): Record quarter with firm global HFC prices; fully utilized capacities with limited scope for volume growth due to quota regime.
2 more points from SRF's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what SRF said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- SRF's capex outlook remains strong for FY27, focusing primarily on a new site in Odisha.
- Planned investments include two plants for new generation gases, with ancillary plants subject to Board approval.
- Expected investment at the Odisha site in the first stage is approximately INR 1,500 crore to INR 2,000 crore.
- The total capex guidance for FY27 is around INR 2,200 crore to INR 2,300 crore.
- The company is proactive in expanding pharma intermediate capacity, with a planned second pharma intermediate plant involving a capex of INR 180 crore.
2 more points from SRF's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Order Book & Pipeline
See what SRF said on order book & pipeline — free account, 30 seconds.
SRF — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.9K Cr, net profit ₹509 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SRF Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio Solutions Ltd (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
- Jubilant Agri & Consumer Products Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations: INR 4,510 million, up 13% YoY from INR 3,975 million in Q3 FY25 (Page 20). Key investor presentation takeaways from Jubilant Ag
Arthneeti Pro · Annual
SRF and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were SRF Q3 FY26 results?
Chemicals Business: Revenue grew 22% YoY in Q3 FY26, driven by refrigerant volumes and realizations. - Specialty Chemicals: Facing pricing pressure due to Chinese competition; volumes protected, but growth delayed. SRF is confident about sustainable growth driven by its robust pipeline, clear strategy, and committed execution team.
What is SRF share price analysis?
SRF currently shows a neutral. The stock trades at a P/E of 34.0 with a market cap of ₹76,238 Cr. Investors should review the full earnings analysis for detailed insights.
Is SRF planning capital expenditure?
SRF's capex outlook remains strong for FY27, focusing primarily on a new site in Odisha.
Keep SRF on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.